Relationship between hyperglycemia, insulin resistance and serum apoptosis marker m30- antigen in patients with type 2 diabetes mellitus Hyperglycemia Level and M30- Antigen

Main Article Content

İhsan Boyacı
Türkan Yiğitbaşı
Handan Ankaralı

Abstract

Objective: The amount of evidence suggests that the apoptosis marker M30-antigen (an antibody that recognizes the cytokeratin-18 fragment) has an association with hyperglycemia.


Material and Methods: In this study, serum M30 levels of 145 patients diagnosed with prediabetes (n = 28) and type 2 diabetes, which was divided into four groups according to their HbA1c levels, were measured. The health control group (n = 24) was composed of healthy individuals. Serum concentrations of M30 antigen were measured using an enzyme-linked immunosorbent assay system and expressed as mean ± SD. HbA1c concentration was determined by boronate affinity technology according to NGSP standards.


Results: M30 levels were comparable in the healthy control group (64,39±3,9 U/L) and prediabetes group (82,07±13,7). Type 2 diabetes Groups A, B, C, and D had levels of 109,38±16 U/L, 117,46±14,3 U/L, 173,69±48,1 U/L, and 163,40±37,3 U/L, respectively. The analysis of the data has shown that serum levels of M30 in the control and prediabetes groups were significantly lower than Type 2 diabetes Groups C and D (p=0.043). When all groups were taken into consideration, a significant relationship was found between HbA1c and serum M30 levels (r=0.231, p=0.002).


Conclusion: Apparently, the increase in glycemia is followed by a rise in the serum levels of the, suggesting that apoptosis occurs as a secondary effect immediately after hyperglycemia.

Downloads

Download data is not yet available.

Article Details

How to Cite
Boyacı, İhsan, Yiğitbaşı, T., & Ankaralı, H. (2021). Relationship between hyperglycemia, insulin resistance and serum apoptosis marker m30- antigen in patients with type 2 diabetes mellitus. Medical Science and Discovery, 8(4), 237-246. https://doi.org/10.36472/msd.v8i4.524
Section
Research Article

References

1. International Diabetes Atlas [Internet]. Brussels: IDF; [2019; cited 2021 Feb 19]. Available from: https://www.diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html

2. Allen DA, Yaqoob MM, Harwood SM. Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. Vol. 16, Journal of Nutritional Biochemistry. 2005. p. 705–13. Available from: https://doi.org/10.1016/j.jnutbio.2005.06.007

3. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet [Internet]. 2014 Mar;383(9922):1068–83. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673613621546

4. Anuradha R, Saraswati M, Kumar KG, Rani SH. Apoptosis of Beta Cells in Diabetes Mellitus. DNA Cell Biol [Internet]. 2014;33(11):743–8. Available from: http://online.liebertpub.com/doi/abs/10.1089/dna.2014.2352

5. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer. 2003;39:769–74. Available from: https://doi.org/10.1016/S0959-8049(02)00865-1

6. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology [Internet]. 2006;44(1):27–33. Available from: http://doi.wiley.com/10.1002/hep.21223

7. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett [Internet]. 2004 Oct 8 [cited 2015 Dec 13];214(1):1–9. Available from: http://www.sciencedirect.com/science/article/pii/S0304383504005002

8. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem [Internet]. 2004 Jul 1 [cited 2019 Feb 7];37(7):529–40. Available from: https://www.sciencedirect.com/science/article/pii/S0009912004001316

9. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2014;44(8):854–62. Available from: https://doi.org/10.1111/hepr.12197

10. Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, et al. Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase Levels. J Clin Gastroenterol [Internet]. 2010 Jan [cited 2017 Dec 4];44(6):440–7. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004836-900000000-99432

11. Hoffmanová I, Sánchez D, Hábová V, Anděl M, Tučková L, Tlaskalová-Hogenová H. Serological Markers of Enterocyte Damage and Apoptosis in Patients With Celiac Disease, Autoimmune Diabetes Mellitus and Diabetes Mellitus Type 2. Physiol Res [Internet]. 2015 [cited 2017 Nov 18];64:537–46. Available from: http:// www.biomed.cas.cz/physiolres

12. Chamberlain JJ, Rhinehart AS, Shaefer CF, Neuman A. Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med [Internet]. 2016 Apr 19 [cited 2019 Feb 7];164(8):542. Available from: http://annals.org/article.aspx?doi=10.7326/M15-3016

13. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-Cell apoptosis in humans with type 2 diabetes. Diabetes [Internet]. 2003;52(January):102–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12502499

14. Li JJ, Lee SHS-K, Kim DK, Jin R, Jung D-S, Kwak S-J, et al. Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. Diabetes [Internet]. 2014 Jan 1 [cited 2015 Dec 13];44(1):1078–87. Available from: http://joi.jlc.jst.go.jp/JST.JSTAGE/jphs/11072FP?from=CrossRef

15. Kaneto H, Katakami N, Matsuhisa M, Matsuoka T. Role of Reactive Oxygen Species in the Progression of Type 2 Diabetes and Atherosclerosis. Mediators Inflamm [Internet]. 2010;2010:1–11. Available from: http://www.hindawi.com/journals/mi/2010/453892/

16. Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, et al. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased  β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 2011;286(29):25467–76. Available from: https://www.jbc.org/article/S0021-9258(19)48537-2/fulltext

17. Liu Z, Stanojevic V, Brindamour LJ, Habener JF. GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity. J Endocrinol [Internet]. 2012 May 1 [cited 2018 Jan 8];213(2):143–54. Available from: http://joe.endocrinology-journals.org/cgi/doi/10.1530/JOE-11-0328

18. Power SE, O’Toole PW, Stanton C, Ross RP, Fitzgerald GF, O', et al. Intestinal microbiota, diet and health. Br J Nutr [Internet]. 2014 Feb 12 [cited 2017 Feb 3];111(03):387–402. Available from: http://www.journals.cambridge.org/abstract_S0007114513002560

19. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes [Internet]. 2002 Jun 1 [cited 2018 Jan 1];51(6):1938–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12031984


20. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC. Relationship Between β -Cell Mass and Fasting Blood Glucose Concentration in Humans. Diabetes Care [Internet]. 2006;29(3):717–8. Available from: http://care.diabetesjournals.org/content/29/3/717.full

21. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes [Internet]. 2009 Apr [cited 2018 Oct 28];58(4):773–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19336687

22. Kim J-Y, Lim D-M, Park H-S, Moon C-I, Choi K-J, Lee S-K, et al. Exendin-4 Protects Against Sulfonylurea-Induced β-Cell Apoptosis. J Pharmacol Sci [Internet]. 2012 [cited 2018 Feb 10];118(1):65–74. Available from: http://joi.jlc.jst.go.jp/JST.JSTAGE/jphs/11072FP?from=CrossRef

23. Civera M, Urios A, Garcia-Torres ML, Ortega J, Martinez-Valls J, Cassinello N, et al. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab Res Rev [Internet]. 2010 Mar 10 [cited 2018 Nov 24];26(3):187–92. Available from: http://doi.wiley.com/10.1002/dmrr.1070

24. Hussien HI, Pasha HF, Mostafa NA. Apoptotic Shards of Cytokeratin 18 Point to Steatohepatitis in Patients with non Alcoholic Hepatic Steatosis [Internet]. Vol. 79, Med J Cairo Univ. 2011 [cited 2018 Nov 24]. 2011;79(2):199-205 [cited 2018 Nov 24]. Available from: http://www.medicaljournalofcairouniversity.com

25. Maiese K. Programming apoptosis and autophagy with novel approaches for diabetes mellitus. Curr Neurovasc Res [Internet]. 2015 [cited 2017 Nov 18];12(2):173–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25742566

26. Holmqvist P, Lundström M, Stål O. Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer. South-East Sweden Breast Cancer Group. Int J Biol Markers [Internet]. 1999 [cited 2018 Jan 8];14(2):84–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10399627

27. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2014;44(8):854–62. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/hepr.12197

28. Mai, Murase-Mishiba Y, Bessho M, Miyawaki M, Imbe H, Tsutsumi C, et al. The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Clin Chim Acta [Internet]. 2014;433:184–9. Available from: https://ac.els-cdn.com/S0009898114001260/1-s2.0-S0009898114001260-main.pdf?_tid=e9b95836-bf8e-11e7-830c-00000aab0f6c&acdnat=1509600798_dea392d4cd2dff138df2bb1684b23590

29. Jones AG, Hattersley AT. The clinical utility of C‐peptide measurement in the care of patients with diabetes. Diabetic Medicine [Internet]. 2013 Jul 23;30(7):803–17. Available from: https://onlinelibrary.wiley.com/doi/10.1111/dme.12159

30. Bhatt MP, Lim Y-C, Kim Y-M, Ha K-S. C-peptide activates AMPKα and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes. Diabetes [Internet]. 2013 Nov [cited 2018 Jan 1];62(11):3851–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23884890

31. Bhatt MP, Lim Y-C, Hwang J, Na S, Kim Y-M, Ha K-S. C-peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation. Diabetes [Internet]. 2013 Jan [cited 2018 Jan 1];62(1):243–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22923476

32. Waldhäusl W. C-peptide as a remedy for diabetic microangiopathy? Diabetes [Internet]. 2013 Jan [cited 2018 Jan 1];62(1):39–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23258913


33. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med [Internet]. 2000 Nov 6 [cited 2018 Jan 31];192(9):1353–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11067883

34. Wang X, Bao W, Liu J, Ouyang Y-Y, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care [Internet]. 2013;36(1):166–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23264288

35. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, et al. Impact of Weight Loss on Inflammatory Proteins and Their Association With the Insulin Resistance Syndrome in Morbidly Obese Patients. Arterioscler Thromb Vasc Biol [Internet]. 2003 Jun 1 [cited 2019 Feb 9];23(6):1042–7. Available from: https://www.ahajournals.org/doi/10.1161/01.ATV.0000073313.16135.21

36. Festa A, D’Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome : The Insulin Resistance Atherosclerosis Study (IRAS). Circulation [Internet]. 2000;102(1):42–47. Available from: https://doi.org/10.1161/01.CIR.102.1.42

37. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol [Internet]. 2007 Feb 14 [cited 2017 Oct 20];13(6):837–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17352011

38. International Expert Committee TIE. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care [Internet]. Virgina :ADA;2009;32(7):1327–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19502545

39. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia [Internet]. 2009;52(1):17–30. Available from: http://link.springer.com/10.1007/s00125-008-1157-y

40. Mostafa SA, Davies MJ, Srinivasan BT, Carey ME, Webb D, Khunti K. Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation? Postgrad Med J [Internet]. 2010;86(1021):656–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20956395